This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
News FDA Updates Law and Advocacy Technology Trends Viewpoints All News Media In-Depth Insights Pharmacist View Script-Ed Expert Interviews Podcasts Conferences Conference Coverage Conference Listing Resources Disease Awareness White Board Video American Pharmacists Month Sponsored Resources CME/CE Partners Publications Drug Topics Journal Total Pharmacy Journal Submission of Articles Events Virtual Events Total Pharmacy Solutions Summit Business Business Strategies Patient Services Pharmacy Inv
New research reveals that while 52 percent of pharmaceutical companies remain in early stages of digitalisation, leading manufacturers are finding innovative ways to overcome data fragmentation and drive operational efficiency. The pharmaceutical manufacturing sector stands at a digital crossroads. Despite significant investment in modern technologies, more than half of companies are still struggling with the fundamentals of digitalisation, according to recent research conducted by Hexagon in pa
News FDA Updates Law and Advocacy Technology Trends Viewpoints All News Media In-Depth Insights Pharmacist View Script-Ed Expert Interviews Podcasts Conferences Conference Coverage Conference Listing Resources Disease Awareness White Board Video American Pharmacists Month Sponsored Resources CME/CE Partners Publications Drug Topics Journal Total Pharmacy Journal Submission of Articles Events Virtual Events Total Pharmacy Solutions Summit Business Business Strategies Patient Services Pharmacy Inv
Adam James, PharmD, and Chris Altman, PharmD, discuss renewed public scrutiny of thimerosal, its limited use in vaccines today, and how new guidance may affect pharmacists and patient confidence moving forward.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
A single national formulary (SNF) for prescribing in England will be in place within the next two years under proposals, the Government has announced. Outlined in the new NHS 10-year plan and backed by the National Institute for Health and Care Excellence (NICE), the SNF will reduce duplication and the ‘postcode lottery’ that has arisen out of locally derived formularies, the Government said.
Bupropion is a prescription medication that affects chemicals in the brain linked to mood and cravings. It’s used to treat a range of conditions, including depression, seasonal mood changes, and even to support smoking cessation. Not all forms of bupropion are the same, and the dosage and purpose can vary depending on the specific product. For example, Wellbutrin XL (bupropion) is a common bupropion product that’s approved by the Food and Drug Administration (FDA) to treat major depressive disor
Congressman Buddy Carter (R-GA) champions the PBM Reform Act of 2025, aiming to enhance drug price transparency and empower pharmacists in healthcare delivery.
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Congressman Buddy Carter (R-GA) champions the PBM Reform Act of 2025, aiming to enhance drug price transparency and empower pharmacists in healthcare delivery.
News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice in Focus: Oncology Pharmacy Practice in Focus: Health Systems Pharmacy Careers All Publications About the Publications Author Submission Submit to
In the first part of his Pharma Commerce video interview, Sean O’Hearen, founder and principal consultant at 1st Line Partners, lays out the systemic gaps in medical and pharmacy education that need to be addressed, along with how academic and clinical institutions can accelerate awareness training in identifying substandard and falsified medicines.
Azithromycin is an antibiotic used to treat certain types of bacterial infections in both adults and children. It’s available as a generic drug or under the brand name Zithromax. In children, the Food and Drug Administration (FDA) has approved azithromycin to treat ear infections, throat and sinus infections, tonsillitis, and community-acquired pneumonia (a type of pneumonia caught outside of a hospital setting).
News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice in Focus: Oncology Pharmacy Practice in Focus: Health Systems Pharmacy Careers All Publications About the Publications Author Submission Submit to
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Once again, ViiV Healthcare has announced steps to widen access to a sought-after HIV medicine in low- and middle-income countries, reflecting ongoing pressure to respond to criticism. Under the latest arrangement , the company is expanding a licensing agreement reached three years ago with the Medicines Patent Pool, which is backed by the United Nations and negotiates licensing rights for manufacturing to generic companies.
Researchers investigated the timing of hypertension diagnosis, exploring how it’s associated with medication prescribing and long-term cardiovascular outcomes.
News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice in Focus: Oncology Pharmacy Practice in Focus: Health Systems Pharmacy Careers All Publications About the Publications Author Submission Submit to
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice in Focus: Oncology Pharmacy Practice in Focus: Health Systems Pharmacy Careers All Publications About the Publications Author Submission Submit to
Subscribe Advertise About us Follow Follow Follow Follow GO Magazine PharmaTimes Magazine Archive Web Exclusives News Competitions Appointments Business Insights Webinars Thought Leadership MHRA approves first oral treatment for hereditary angioedema attacks by John Pinching | 15th Jul 2025 | News Sebetralstat offers injection-free relief for patients aged 12 and over The MHRA has approved sebetralstat (Ekterly) as the first oral, on-demand treatment for hereditary angioedema (HAE) attacks in pa
Azithromycin , sold under brand names like Zithromax , is a common antibiotic used to treat bacterial infections like ear infections, throat infections, and sinusitis. Though generally well-tolerated, some people may feel tired or sluggish after taking azithromycin, which is an uncommon side effect listed on its drug label. We’ll break down how azithromycin works, how it might lead to fatigue, what you can do about it, and what your healthcare provider may consider if it’s not the right fit.
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
The digital landscape has revolutionized the way pharmaceutical brands reach and engage healthcare professionals (HCPs) and patients. In today’s fast-paced environment, digital advertising campaigns are no longer limited to banner ads or static placements—they now leverage AI, real-time analytics, and hyper-personalized content strategies. But how can pharma marketers ensure they are staying ahead without violating regulations or overspending?
Patients with chronic kidney disease (CKD) were more likely to get vaccinated for influenza and pneumococcal following a health care provider’s recommendation.
Pharvaris has announced that its data from its phase 3 study of deucrictibant immediate-release capsules (IR) for the treatment of hereditary angioedema (HAE) attacks will now be released in the fourth quarter of 2025. Pending positive results, the company expects to submit a New Drug Application to the US Food and Drug Administration in the […] The post Pharvaris to report phase 3 data and submit New Drug Application appeared first on Pharmafile.
French biopharma, Osivax, has announced positive results from its phase 2 study, OVX836-004, into OVX836, its broad-spectrum influenza vaccine lead candidate. The results have been published in the journal, Vaccines. In the study, 180 healthy adults aged 18 to 55 years were given either Fluarix Tetra (hemagglutinin antigen-based inactivated influenza vaccine) with a placebo, Fluarix […] The post Osivax publishes positive results from trial of influenza vaccine candidate appeared first on P
Glucagon-like peptide-1 ( GLP-1 ) receptor agonists are a class of drugs that lower blood sugar levels in people with Type 2 diabetes and promote weight loss when used with a healthy diet and exercise. Although health insurance companies tend to cover GLP-1 agonists as a treatment for Type 2 diabetes, coverage for weight loss is less common. That said, insurance formularies can change for a variety of reasons, and it can be frustrating to find that your GLP-1 medication is no longer covered.
In the second part of his Pharma Commerce video interview, Murray Aitken, executive director, IQVIA Institute for Human Data Science, suggests how pharma companies should revise their market access and pricing models to align with the evolving landscape.
Mounjaro (tirzepatide) is a prescription drug approved by the Food and Drug Administration (FDA) to treat Type 2 diabetes. However, because it suppresses appetite, Mounjaro is sometimes prescribed off-label for weight loss. As diabetes medications and weight loss medications like Ozempic , Wegovy , and Mounjaro have become more popular, many women have expressed concern about the possibility of female-specific side effects.
National Institute for Health and Care Excellence (NICE) has recommended Alyftrek ® (deutivacaftor/tezacaftor/vanzacaftor) for eligible NHS patients with cystic fibrosis. The treatment was licensed for UK use in March. Individuals who are six years old and over with at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene can access Alyftrek through NHS England.
Atorvastatin is a generic statin , a class of medications used to lower cholesterol levels and reduce the risk of heart attack and stroke. It is available in generic form and as brand-names Lipitor and Atorvaliq. Like other statins, atorvastatin comes in different doses that correspond to different levels of treatment intensity. Some people may need only a low or moderate-intensity statin prescription, while others may benefit from a higher dose.
Researchers addressed the current trends in prescription drug use and spending among Medicare Advantage beneficiaries during the first year of clinician access to a real-time prescription benefit tool.
Subscribe Advertise About us Follow Follow Follow Follow GO Magazine PharmaTimes Magazine Archive Web Exclusives News Competitions Appointments Business Insights Webinars Thought Leadership NHS England secures access to new cystic fibrosis treatment ALYFTREK by John Pinching | 15th Jul 2025 | News Vertex’s once-daily triple therapy approved for eligible patients aged six and over Vertex Pharmaceuticals has announced a broad reimbursement agreement with NHS England for ALYFTREK (deutivacaftor/tez
Brooklyn Morgan, PharmD, director of state policy at the National Alliance of State Pharmacy Associations, emphasizes the importance of making the pharmacist's voice heard.
Input your email to sign up, or if you already have an account, log in here!
Enter your email address to reset your password. A temporary password will be e‑mailed to you.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content